Breakthrough in Cancer Immunotherapy: Mass-Producing Tumor-Killing NK Cells from Stem Cells
A new strategy developed by Chinese scientists promises to revolutionize cancer treatment by enabling the large-scale production of natural killer (NK) cells, a vital component of the body’s immune defense. This advancement addresses key limitations of current NK cell therapies, potentially making them more accessible, effective, and affordable.
The Power of Natural Killer Cells in Cancer Treatment
Natural killer (NK) cells are crucial for the body’s early defense against viruses and cancer. Their inherent ability to identify and destroy abnormal cells makes them a promising tool in cancer immunotherapy. Researchers are particularly excited about chimeric antigen receptor (CAR)-NK therapy, where NK cells are engineered with lab-designed receptors (CARs) to precisely target and attack cancer cells.
Challenges with Traditional NK Cell Therapies
Traditional methods of obtaining NK cells for therapy rely on mature cells collected from sources like peripheral blood or cord blood. However, these approaches face several hurdles:
- Variability between cells
- Inefficient genetic modification
- High production costs
- Lengthy preparation times
A Novel Approach: Stem Cell-Derived NK Cells
A team led by Professor WANG Jinyong at the Institute of Zoology of the Chinese Academy of Sciences has pioneered a new approach. Instead of modifying mature NK cells, they start with CD34+ hematopoietic stem and progenitor cells (HSPCs) from cord blood. This innovative technique generates induced NK (iNK) cells and CAR-engineered iNK (CAR-iNK) cells.
The Three-Step Expansion and Differentiation Process
The researchers developed a three-stage system to maximize cell production:
- Expansion: CD34+ HSPCs (or CD19 CAR-transduced HSPCs) are expanded using irradiated AFT024 feeder cells, multiplying roughly 800- to 1,000-fold within 14 days.
- Commitment: Expanded cells are cultured with OP9 feeder cells to create artificial hematopoietic organoid aggregates, promoting efficient NK lineage commitment and development.
- Maturation: Cells committed to becoming NK cells are allowed to mature and further multiply, resulting in highly pure iNK or CAR-iNK cells expressing endogenous CD16.
Massive Cell Output and Reduced Costs
Remarkably, a single CD34+ HSPC can generate up to 14 million iNK cells or 7.6 million CAR-iNK cells. Researchers estimate that one-fifth of a typical cord blood unit could yield enough cells for thousands of treatment doses. This method significantly reduces the amount of viral vector needed for CAR engineering – using approximately 1/140,000 to 1/600,000 of the amount typically required for mature NK cells.
Promising Results in Leukemia Models
Laboratory testing demonstrated the potent tumor-killing ability of both iNK and CAR-iNK cells. In mouse models of human B-cell acute lymphoblastic leukemia (B-ALL), CD19 CAR-iNK cells reduced tumor growth and extended survival.
China’s Role in Advancing NK Cell Immunotherapy
China is rapidly becoming a global leader in biotechnology and advanced cancer care, offering accessible and cutting-edge NK cell immunotherapy. Treatment packages in China generally range from $18,000 to $30,000, significantly lower than the $85,000+ cost in the United States.
Looking Ahead
This breakthrough from the Chinese Academy of Sciences represents a significant step forward in cancer immunotherapy. By overcoming the limitations of traditional NK cell therapies, this new approach has the potential to build these life-saving treatments more widely available and affordable for patients worldwide.
Keep reading